Sage Therapeutics Inc (NASDAQ:SAGE) shares, rose in value, with the stock price up by 0.27% to the previous day’s close as strong demand from buyers drove the stock to $9.23.
Actively observing the price movement in the recent trading, the stock is buoying the session at $9.21, falling within a range of $9.1603 and $9.25. The value of beta (5-year monthly) is 0.175. Referring to stock’s 52-week performance, its high was $13.47, and the low was $4.62. On the whole, SAGE has fluctuated by 32.12% over the past month.
With the market capitalization of Sage Therapeutics Inc currently standing at about $578.32 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Apr-29.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that SAGE’s technical picture suggests that short-term indicators denote the stock is a 100% Buy on average. However, medium-term indicators have put the stock in the category of 100% Buy while long-term indicators on average have been pointing out that it is a 100% Buy.
The stock’s technical analysis shows that the price of SAGE currently trading nearly 3.43% and 20.87% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 72.88, while the 7-day volatility ratio is showing 1.10% which for the 30-day chart, stands at 2.04%. Furthermore, Sage Therapeutics Inc (SAGE)’s beta value is 0.26.
A comparison of Sage Therapeutics Inc (SAGE) with its peers suggests the former has fared considerably weaker in the market. SAGE showed an intraday change of 0.27% in today’s session so far, and over the past year, it grew by 70.07%%.
Data on historical trading for Sage Therapeutics Inc (NASDAQ:SAGE) indicates that the trading volumes over the past 10 days have averaged 2.0 and over the past 3 months, they’ve averaged 1.59 million. According to company’s latest data on outstanding shares, there are 62.54 million shares outstanding.
Nearly 12.03% of Sage Therapeutics Inc’s shares belong to company insiders and institutional investors own 85.16% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 5.25 million shares as on 2025-06-13, resulting in a short ratio of 7.37. According to the data, the short interest in Sage Therapeutics Inc (SAGE) stood at 934.00 of shares outstanding as of 2025-06-13; the number of short shares registered in 2025-05-15 reached 5.01 million. The stock has fallen by -19.49% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the SAGE stock heading into the next quarter.
